FDAnews
www.fdanews.com/articles/85271-adipogenix-achieves-third-milestone-in-collaboration-with-johnson-johnson

ADIPOGENIX ACHIEVES THIRD MILESTONE IN COLLABORATION WITH JOHNSON & JOHNSON

March 14, 2006

AdipoGenix Inc., a biopharmaceutical company developing small molecule therapies for obesity, type 2 diabetes and associated morbidities, today announced the achievement of its third milestone in the Company's drug discovery collaboration with Johnson & Johnson (J&J). In November 2002, AdipoGenix and J&J entered a drug discovery collaboration in which AdipoGenix has utilized its proprietary human fat cell-based technologies for discovering compounds that reduce the fat content of human fat cells from J&J's compound collection.
PR Newswire